Overtreatment of men with early-stage prostate cancer and limited life expectancy

Authors

  • Matthew R. Danzig BS,

    1. Department of Urology, Herbert Irving Cancer Center, Columbia University College of Physicians and Surgeons, New York, New York
    Search for more papers by this author
  • James M. McKiernan MD

    Corresponding author
    1. Department of Urology, Herbert Irving Cancer Center, Columbia University College of Physicians and Surgeons, New York, New York
    • Corresponding author: James M. McKiernan, MD, Department of Urology, Columbia University, 161 Fort Washington Avenue, Herbert Irving Pavilion, 11th Floor, New York, NY 10032; Fax: (212) 305-0106; jmm23@cumc.columbia.edu

    Search for more papers by this author

  • See referenced original article on pages 3642–50, this issue.

Abstract

The accompanying article by Daskivich et al explores, with rigorous methodology, the issue of the overtreatment of men with early stage prostate cancer and limited life expectancy. Particular attention should be paid to the finding of the predominance of radiotherapy in this group, which should not be considered a benign alternative to surgery given the evidence for long-term morbidity after this treatment.

Ancillary